Posaconazole Juno (Posaconazole)

posaconazole 100 mg modified release tablet, 24 · ORAL · PBS code 10460M

AUTHORITY_REQUIRED

What it costs

AU$104.77 PBS-determined price per 24 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2020-12-01.
• Repeats: 0.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Invasive aspergillosis

Patient must be unable to tolerate alternative therapy; or

Patient must have disease refractory to alternative therapy; AND

Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Prophylaxis of invasive fungal infections including both yeasts and moulds

Patient must be considered at high risk of developing an invasive fungal infection due to anticipated neutropenia (an absolute neutrophil count less than 500 cells per cubic millimetre), for at least 10 days whilst receiving chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome; or

Patient must be considered at high risk of developing an invasive fungal infection due to having acute graft versus host disease (GVHD) grade II, III or IV, or extensive chronic GVHD, and receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant; AND

Treatment of neutropenia should continue until recovery of the neutrophil count to at least 500 cells per cubic millimetre.

Patients who have had a previous invasive fungal infection should have secondary prophylaxis during subsequent episodes of neutropenia.

No more than 6 months therapy per episode will be PBS-subsidised

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Fungal infection

The condition must be fusariosis; or

The condition must be zygomycosis; or

The condition must be coccidioidomycosis; or

The condition must be chromoblastomycosis; or

The condition must be mycetoma; AND

Patient must be unable to tolerate alternative therapy; or

Patient must have disease refractory to alternative therapy; AND

Sponsor: Juno Pharmaceuticals Pty Ltd ABN 55 156 303 650

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.